Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Cash & Equivalents: 2019-2023

Historic Cash & Equivalents for ADC Therapeutics (ADCT) over the last 5 years, with Sep 2023 value amounting to $310.4 million.

  • ADC Therapeutics' Cash & Equivalents rose 81401.60% to $310.4 million in Q3 2023 from the same period last year, while for Sep 2023 it was $310.4 million, marking a year-over-year increase of 81401.60%. This contributed to the annual value of $326.4 million for FY2022, which is 30.03% down from last year.
  • According to the latest figures from Q3 2023, ADC Therapeutics' Cash & Equivalents is $310.4 million, which was down 10.68% from $347.5 million recorded in Q2 2023.
  • ADC Therapeutics' Cash & Equivalents' 5-year high stood at $466.5 million during Q4 2021, with a 5-year trough of $149,517 in Q3 2019.
  • Moreover, its 3-year median value for Cash & Equivalents was $530,194 (2021), whereas its average is $160.4 million.
  • In the last 5 years, ADC Therapeutics' Cash & Equivalents tumbled by 99.54% in 2021 and then spiked by 92,132.03% in 2023.
  • ADC Therapeutics' Cash & Equivalents (Quarterly) stood at $115.6 million in 2019, then soared by 230.68% to $494,416 in 2020, then increased by 7.24% to $466.5 million in 2021, then tumbled by 30.03% to $326.4 million in 2022, then skyrocketed by 81,401.60% to $310.4 million in 2023.
  • Its Cash & Equivalents was $310.4 million in Q3 2023, compared to $347.5 million in Q2 2023 and $310.5 million in Q1 2023.